TOPAZ: Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (H-45698)
Description
TOPAZ: A Phase I/II Study of Dermaprazole for Radiation Dermatitis in Post-Mastectomy Breast Cancer and Head and Neck Cancer Patients
Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. The aim of this study is to investigate the safety and tolerability (Phase I) and preliminary efficacy (Phase II) of prophylactic esomeprazole cream (termed "Dermaprazole") in patients who require radiation for breast cancer in the adjuvant setting.
For more information: https://clinicaltrials.gov/study/NCT05269160
Contact
Phone 1: 713–798–2878
IRB: H-45698
Status:
Active
Created: